Exploring the Potential of Phytocannabinoids Against Multidrug-Resistant Bacteria
- PMID: 40647911
- PMCID: PMC12251955
- DOI: 10.3390/plants14131901
Exploring the Potential of Phytocannabinoids Against Multidrug-Resistant Bacteria
Abstract
The rapid emergence of multidrug-resistant (MDR) bacterial pathogens poses a critical threat to global health, creating an urgent need for novel antimicrobial agents. In this study, we evaluated a small library of natural and semisynthetic phytocannabinoids against a broad panel of MDR Gram-positive bacterial strains, evidencing very good activity in the low µM range. We provide evidence of the antibacterial activity of the two separated enantiomers of cannabidiol, offering novel insights into the stereochemical aspects of their bioactivity. To investigate the possible molecular targets and clarify the mechanism of action, we employed Inverse Virtual Screening (IVS), a computational approach optimized for predicting potential protein-ligand interactions, on three selected MDR bacterial species. Interestingly, key targets belonging to important bacterial metabolic pathways and defense mechanisms were retrieved, and the results were used to rationalize the observed biological activities. To the best of our knowledge, this study marks the first application of IVS to microorganisms, offering a novel strategy for identifying bacterial protein targets. The results pave the way for future experimental validation, structure-based drug design, and the development of novel antibacterial agents.
Keywords: antibacterial activity; cannabinoids; inverse virtual screening; multidrug resistance.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Anti-bacterial activity of dermcidin in human platelets: suppression of methicillin-resistant Staphylococcus aureus growth.Microbiol Spectr. 2025 Jul;13(7):e0327324. doi: 10.1128/spectrum.03273-24. Epub 2025 May 27. Microbiol Spectr. 2025. PMID: 40422282 Free PMC article.
-
A systematic review on natural products with antimicrobial potential against WHO's priority pathogens.Eur J Med Res. 2025 Jul 1;30(1):525. doi: 10.1186/s40001-025-02717-x. Eur J Med Res. 2025. PMID: 40597250 Free PMC article.
-
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2. Cochrane Database Syst Rev. 2022. PMID: 35470432 Free PMC article.
-
Identification of Compounds With Potential Dual Inhibitory Activity Against Drug Efflux Pumps in Resistant Cancer Cells and Bacteria: Protocol for a Systematic Review.JMIR Res Protoc. 2025 Jun 5;14:e66197. doi: 10.2196/66197. JMIR Res Protoc. 2025. PMID: 40472353 Free PMC article.
-
High-throughput clinical antimicrobial susceptibility testing and drug-resistant subpopulation detection in Gram-negative bacteria.Microbiol Spectr. 2025 Jul;13(7):e0001125. doi: 10.1128/spectrum.00011-25. Epub 2025 Jun 5. Microbiol Spectr. 2025. PMID: 40470969 Free PMC article.
References
-
- Ahmed S.K., Hussein S., Qurbani K., Ibrahim R.H., Fareeq A., Mahmood K.A., Mohamed M.G. Antimicrobial resistance: Impacts, challenges, and future prospects. J. Med. Surg. Public Health. 2024;2:100081. doi: 10.1016/j.glmedi.2024.100081. - DOI
-
- Klein E.Y., Impalli I., Poleon S., Denoel P., Cipriano M., Van Boeckel T.P., Pecetta S., Bloom D.E., Nandi A. Global trends in antibiotic consumption during 2016–2023 and future projections through 2030. Proc. Natl. Acad. Sci. USA. 2024;121:e2411919121. doi: 10.1073/pnas.2411919121. - DOI - PMC - PubMed
-
- Kakkar A.K., Shafiq N., Singh G., Ray P., Gautam V., Agarwal R., Muralidharan J., Arora P. Antimicrobial stewardship programs in resource constrained environments: Understanding and addressing the need of the systems. Front. Public Health. 2020;8:140. doi: 10.3389/fpubh.2020.00140. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources